EP1863835A2

EP1863835A2 - Vaccine and antibodies against parasitic nematodes

Info

Publication number: EP1863835A2
Application number: EP06725222A
Authority: EP
Inventors: Christina Strube; Georg Von Samson-Himmelsterna; Thomas Schnieder
Original assignee: STIFTUNG TIERARZTLICHE HOCHSCHULE HANNOVER
Current assignee: STIFTUNG TIERARZTLICHE HOCHSCHULE HANNOVER
Priority date: 2005-03-22
Filing date: 2006-03-22
Publication date: 2007-12-12
Also published as: WO2006100257A3; BRPI0608889A2; WO2006100257A2; EP1705186A1; MX2007011667A

Abstract

The present invention relates to a vaccine capable of providing immunoprotection against Dictyocaulus viviparus in cattle and use of the vaccine to produce specific antibody against Dictyocaulus viviparus. The vaccine provides the advantage of eliciting an immune reaction against inhibited and non-inhibited larvae of Dictyocaulus viviparus and is characterized by comprising epitopes obtainable from PNMT (phenyl ethanolamine-N-methyltransferase) of Dictyocaulus viviparus. In a further aspect, the present invention also provides antibody specific for said vaccine.

Description

Vaccine and antibodies against parasitic nematodes

The present invention relates to a vaccine against parasitic nematodes of the genus Strongylida, especially to Dictyocaulus spp., preferably Dictyocaulus fllaria, Dictyocaulus arnfieldi, Dictyocaulus capreolus, Dictyocaulus cameli, Dictyocaulus africanus, and most preferably to Dictyocaulus viviparus. For the purposes of the invention, reference to Dictyocaulus spp. includes the aforementioned species. Further, the invention relates to the use of antigenic peptides for analytical and diagnostic purposes to detect an infection by parasitic nematodes of the genus Strongylida, especially by Dictyocaulus spp. and to provide a method for providing immunoprotection against parasitic nematodes of the genus Strongylida, especially Dictyocaulus spp.

Further, the present invention relates to a process for producing a vaccine suitable for providing immunity against infections by parasitic nematodes of the genus Strongylida, especially Dictyocaulus spp. and for the production of specific antibodies against parasitic nematodes of the genus Strongylida, especially Dictyocaulus spp. as well as antibodies, specifically directed against parasitic nematodes of the genus Strongylida, especially Dictyocaulus spp. In greater detail, the present invention provides a combination of antigenic peptides that are immunoreactive components of Dictyocaulus spp., especially Dictyocaulus viviparus that can be used for producing a vaccine for producing an immune response and antibody directed against parasitic nematodes of the genus Strongylida, especially Dictyocaulus spp. and Dictyocaulus viviparus.

State of the art

Dictyocaulus viviparus, a bovine lungworm is the cause of parasitic bronchitis impairing the development of infected animals, often leading to death of calves.

Dictyocaulus viviparus has a development cycle of a first larval stage, which is secreted by the faeces of infected host animals. Under appropriate climatic circumstances these first stage larvae develop within a week into the second larval stage and a third larval stage, which are infectious larvae.

The infection of cattle is by ingestion of third stage lungworm larvae, which are activated by contact with the gall bile of the host, enabling larvae to pass intestinal mucosa and move through the lymphoid system to the mesenteric lymph nodes, where fourth stage larvae develop by skinning. Larvae of the fourth stage, via passage through the heart reach the lung, where larvae bore into the alveoli. Within the alveoli, larvae skin to develop into pre-adult fifth stage larvae and reach bronchioli and bronchial tubes at about 1 week post infection (p. L). After an intensive growth phase reproducible adult lung worms occur 3 to 4 weeks p.i.

Worm eggs reach the pharynx via the tracheal epithelia and are swallowed by the host animal and a small proportion is coughed out. During the passage through stomach and intestine, first larvae hatch and reach the pasture with faeces. At temperatures below 8 °C in the environment, following ingestion by the novel host, an inhibition of the development occurs in early pre-adult stage larvae.

The inhibition of the development of Dictyocaulus viviparus is at least in part caused by climatic conditions which are unfavourable for the development and survival of active stages outside a host, like low temperatures (winter inhibition) or at high temperatures or very dry weather (dry season inhibition).

To-date, a vaccine against Dictyocaulus viviparus consists of larvae isolated from the faeces of infected animals, which larvae are attenuated by irradiation at 400 Gray preventing a development to the adult stage. However, production of this vaccine uses the artificial infection of calves to produce larvae secreted in the faeces and is rather costly. Further, a disadvantage of the known live vaccine is its limited shelf life of about four months.

Liddell et al. (Extracellular and cytoplasmic Cu/Zn superoxide dismutases from Haemonchus contortus, Parasitology 116, 383-394 (1998)) cite the immunological importance of SOD from Dictyocaulus viviparus for the immunization of cattle. In addition, a combination of cytosolic and extracellular Cu/Zn superoxide dismutases is used as a vaccine against Haemonchus contortus.

For paramyosin, full-length and fragmented paramyosin from Taenia solium have been described in detail as a possible vaccine against cysticercosis (Vazquez-Talavera et al., Characterisation and protective potential of the immune response to Taenia solium in a murine model of cysticercosis, Infection and Immunity, 5412-5416 (2001)). However, the present inventors have found that the paramyosin gene of Taenia solium has only limited homology to the newly identified paramyosin gene of Dictyocaulus viviparus.

In contrast to the suggested suitability of paramyosin from Taenia solium as a possible vaccine against schistosoma and filaria, Pearce et al. (Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen, PNAS 85, 5678-5682 (1988)) demonstrated that paramyosin from Mercenaria mercenaria, a heterologous paramyosin to the one from Schistosoma mansoni, did not induce a protective immune response in mice.

Another paramyosin that has been suggested for use as an antigen against a parasitic infection is paramyosin of Brugia malayi (Nanduri et al., The Journal of Immunology, 143, 3359-336 (1989) Paramyosin enhanced clearance of Brugia malayi microfilaremia in mice). Although classified as a nematode, Brugia, living in the blood of its human hosts, do not belong to the stem of Strongylida, and have a different life cycle from Strongylida. A further hint for the importance of paramyosin for immunoprotection against Brugia malayi comes from Li et al., The Journal of Immunology 150, 1881-1885 (1993) analyzing the immunoprotection obtained after immunization with irradiated larvae or with paramyosin of Brugia malayi.

McManus et al. (A vaccine against Asian schistosomiasis, Parasitology International 53, 163- 173 (2004)) relate to the potential use of paramyosin as an antigenic compound obtainable from Schistosoma japonicum to provide protective immunity against several Schistosoma. McManus et al. preferably relate to regions of high homology of paramyosins from Schistosoma.

Investigating paramyosin as a candidate vaccine antigen against the human parasite Schistosoma japonicum, Ramirez et al. (Parasite Immunology 18, 49-52 (1996)) could show that the schistosome myosin as well as paramyosin from the nematode Mercenaria did not induce immunoprotection against Schistosoma japonicum. The finding that vaccination with paramyosin from Schistosoma japonicum in contrast to paramyosin from Schistosoma mansoni elicits a better protective immune response indicates that the origin of the paramyosin determines its specificity for the respective parasite species. In accordance with suggestions by Ramirez et al. to test the immunoprotective potential elicited by paramyosin from one strain of Schistosoma japonicum even against different strains, it is reasonable to assume that the immunologic importance of paramyosin as an antigen for protective immunity is limited to the specific Schistosome species, possibly even to the specific strain under investigation.

In contrast to the state of art making reference to paramyosin obtained from a certain species of trematodes and cestodes, the present invention refers to paramyosin obtainable from Dictyocaulus viviparus, belonging to the class of Strongylida, for use as an antigenic vaccine component to elicit an immunoreaction against Strongylida, preferably against Dictyocaulus spp.. It is known that the parasites reported to be under investigation, e.g. Taenia solium, Schistosoma mansoni, Schistosoma japonicum and Brugia malayi each have very different development cycles infect different hosts and cause different diseases from Strongylida, especially Dictyocaulus viviparus. The immunoreactivity of SOD of Dictyocaulus viviparus is known from Britton et al. (Superoxide dismutase (SOD) activity of Dictyocaulus viviparus and its inhibition by antibody from infected and vaccinated bovine hosts, Parasitology, 109, 255-261 (1994)). SOD activity was detected in PBS soluble extracts of L3 and adult stages of Dictyocaulus viviparus as well as in excretory secretory products of adult stages. When analyzing SOD by native polyacrylamide gel electrophoresis, different distributions of isoenzymes were found for adult extract in comparison to excretory secretory products. The excretory secretory isoenzyme of SOD was demonstrated to be antigenic by immune reaction with IgG antibody obtained from serum of infected or vaccinated bovine hosts.

However, the present invention refers to a defined SOD, namely the extracellular SOD obtainable from Dictyocaulus viviparus, for use as a vaccine component.

Objects of the invention

It is an object of the present invention to provide a vaccine composition effectively providing immunoprotection against the parasites of the genus Strongylida, especially against Dictyocaulus viviparus. Due to the simultaneous occurrence of inhibited and non- inhibited larval stages of Dictyocaulus viviparus, it is a preferred object of the present invention to provide a vaccine composition that provides immunoprotection against both inhibited and non- inhibited stages of the lungworm.

It is also an object of the present invention to provide a vaccine effective against Strongylida, especially against Dictyocaulus viviparus, which can be produced without artificial infection of host animals, preferably resulting in a vaccine having improved stability during storage.

It is a further object of the present invention to provide antibody reactive with both inhibited and non-inhibited stages of Strongylida, especially of Dictyocaulus viviparus. Such antibody can be used for diagnostic purposes to detect an infection in ruminants, especially in cattle, independent of the development stage of Strongylida, especially Dictyocaulus viviparus. As a further application of such antibody, passive immunization is desired to provide passive immunity or to support the immune defence of the host against Strongylida, especially Dictyocaulus spp.. As a further object, the present invention seeks to provide a method for producing antigenic protein for use in vaccines eliciting protection against Strongylida, especially Dictyocaulus spp.

General description of the invention

In general, the present invention provides a vaccine capable of eliciting an immune response in cattle against Strongylida effective to reduce the excretion of larvae from infected animals and to reduce the worm burden of infected animals. Accordingly, immunization of cattle with a vaccine according to the present invention reduces the effects of an infection with Strongylida, especially Dictyocaulus spp., preferably up to full protection against infection, for example protection against the re-infection syndrome.

In a first embodiment, the present invention provides a vaccine suitable for providing immunoprotection against Strongylida, especially Dictyocaulus spp., comprising protein containing immunogenic epitopes of at least one of phenyl ethanolamine-N-methyltransferase (PNMT), paramyosin, and extra-cellular copper-zinc superoxide dismutase (SOD), all obtainable from the respective genes of Strongylida, especially Dictyocaulus spp..

The epitopes of the vaccine can be provided in the form of complete or partial translation products of the respective genes encoding PNMT, paramyosin, and SOD, respectively. Further, fusion peptides can be used to provide epitopes of one or a combination of the original genes. Such fusion peptides can be translated from synthetically produced nucleic acid sequences encoding a non-natural combination of epitopes derivable from the genes encoding PNMT, paramyosin and SOD. Epitopes can be identified according to standard practice, e.g. by computer-assisted analysis for immunogenic protein regions and/or by testing the immunogenicity of protein portions.

Accordingly, in the following description, the terms SOD, PNMT and paramyosin refer to the expression products of the respective genes obtainable from Strongylida, preferably from Dictyocaulus sp., especially from Dictyocaulus viviparus, and derivatives thereof having immunoreactivity, e.g. peptides comprising epitopes of the aforementioned gene products which are immunoreactive at least in cattle. It was also shown that a combination of epitopes from at least two, preferably three, peptides from the group of PNMT, SOD, and paramyosin resulted in a stronger immunoprotection than a vaccine comprising the epitopes of only one of the aforementioned immunogenic proteins. Accordingly, it is preferred that the vaccine comprises epitopes of at least two of PNMT, SOD, and paramyosin obtainable from the Strongylida, preferably from Dictyocaulus viviparus. Even more preferred, the vaccine comprises PNMT and one or both of SOD, and paramyosin in order to provide protection against both inhibited and non- inhibited stages of Strongylida, especially Dictyocaulus viviparus.

The vaccine compositions can be used for the treatment of seronegative and/or infected animals.

In addition to eliciting an antibody response, it is preferred to provide immunoprotection in ruminants, especially in cattle against Strongylida, especially Dictyocaulus spp. by eliciting a cellular immune response. In accordance with analyses of cattle immunized with vaccine compositions according to the present invention, it has been found that a significant reduction of the worm burden of Dictyocaulus viviparus after artificial infection could be reached in comparison to non- vaccinated control animals. However, the reduction of the worm burden could not only be assigned to antibody titers and, accordingly, it is assumed that the vaccine compositions are able to elicit a cellular immune response in cattle.

In one aspect of the first embodiment, the present invention is focused on the immunoreactivity of paramyosin obtainable from Strongylida, especially Dictyocaulus viviparus. Although Strongylida belong to a different stem of helminths than the genera investigated in the known state of art for their immunoreactivity in respect of their specific paramyosin, the present inventors have found that the paramyosin obtainable from Strongylida, especially paramyosin of Dictyocaulus viviparus is a suitable antigen for eliciting an at least partially protective immune response in ruminants, especially in cattle.

In a further aspect of the first embodiment, the present invention is based on the finding that a combination of paramyosin and SOD obtainable from Dictyocaulus viviparus, which are both predominantly expressed in the non-inhibited larval stage of Dictyocaulus viviparus, can induce an improved immunoreaction in cattle, preferably sufficient to provide immunoprotection against infection by Strongylida, preferably Dictyocaulus spp.. In its preferred embodiment, the first embodiment of the present invention is based on the finding that PNMT is predominantly expressed, i.e. is characteristic for inhibited larval stages at least of Dictyocaulus viviparus and elicits an immune reaction in ruminants, whereas paramyosin and SOD are preferentially expressed in Strongylida, especially in Dictyocaulus viviparus, during their non- inhibited stages.

Therefore, it is preferred that the vaccine contains epitopes of PNMT in combination with at least one of SOD and paramyosin, preferably in combination with at least paramyosin, obtainable from Strongylida, especially from Dictyocaulus viviparus. When present in combination with at least one of SOD and paramyosin, the vaccine comprising PNMT is more effective to elicit an immune response in cattle against non-inhibited and inhibited stages of Strongylida, especially against Dictyocaulus spp..

In addition to epitopes of PNMT in combination with SOD and/or paramyosin, the vaccine can comprise epitopes of acetylcholine esterase (ACE), major sperm protein (MSP) and/or protein disulfide isomerase (PDI) obtainable from Strongylida, especially from Dictyocaulus viviparus. The epitopes derivable from ACE, MSP and PDI may be present in the vaccine in the form of the translation products of the respective natural gene sequences, or as partial translation products or as portions of a fusion peptide as described for PNMT, SOD and paramyosin. Such a fusion peptide may comprise specific epitopes in a new, i.e. non-natural arrangement.

In addition to the immunogenic peptides mentioned hereinabove, the vaccine according to the invention may comprise adjuvants, e.g. Alum, more preferred Quil A, and further known additives like preservatives and antioxidants.

Further, the present invention provides a method for producing vaccine compositions suitable for eliciting a partial, preferably a complete immunoprotection against Strongylida, e.g. against Dictyocaulus spp., which method is characterized by providing the specific immunoreactive proteins of the invention. For production, heterologous expression of each of PNMT, paramyosin and/or SOD, optionally each of ACE, MSP and PDI, each of the aforementioned peptides as complete or partial translation products of the natural respective genes in a microorganism is preferred. For heterologous expression and subsequent purification steps of the immunoreactive proteins, nucleic acid sequences encoding amino acid sequences may be added or deleted, for example a tag for affinity purification like a poly- histidine sequence may be added for ease of purification, or non- immunogenic regions may be deleted. Modifications of the immunoreactive proteins of the invention can be practised as long as the immunoreactive properties remain essentially unchanged, e.g. as long as the specific epitopes of PNMT, paramyosin, and/or SOD optionally of ACE, MSP and/or PDI are not impaired with respect to their antigenicity.

In a second embodiment, the present invention provides antibody preparations directed against the antigenic proteins of the vaccine compositions according to the first embodiment. Such antibody preparations are specific for at least one of PNMT, SOD and paramyosin or, alternatively, specific for two or all three of paramyosin, SOD, and PNMT, preferably including specificity against PNMT in combination with at least one of SOD and PNMT. Accordingly, these antibody preparations are immunoreactive with both protein expressed in the inhibited state as well as with protein expressed in the non-inhibited state of Dictyocaulus spp..

These antibody compositions can be used to provide passive immunization of host animals against Strongylida, especially against Dictyocaulus viviparus, e.g. for treatment of seronegative and/or infected animals. Further, these antibody compositions can be used for analytical purposes, i.e. for detecting an infection of ruminants by Strongylida like Dictyocaulus viviparus.

Detailed description of the invention

The examination of preferential gene transcription of third stage larvae in an inhibited (L3i) and a non-inhibited (L3ni) stage of Dictyocaulus viviparus demonstrated that PNMT, SOD and paramyosin are differentially expressed in third stage larvae, with PNMT characteristic for the inhibited stage and SOD as well as paramyosin characteristic for the non- inhibited stage, respectively. In accordance with the differential expression, the genes are transcribed differentially according to the status of the inhibition.

An immunological reaction in ruminants against each of the proteins PNMT, SOD, and paramyosin was shown by antibody production in response to immunization with each of these proteins, or a combination thereof, in calves originally having a negative immune status to Dictyocaulus viviparus. Further to the induction of an immune response against PNMT, SOD and/or paramyosin in a calf, a specific immune reaction could also be induced by immunizing ruminants, for example cattle, with immunoreactive portions of said proteins, e.g. synthetic peptides or comprising epitopes eliciting a specific antibody response.

Vaccination was done by i.m., i.v., i.p. injection of the peptides in admixture with a suitable adjuvant, e.g. Quil A. However, other routes of administration can be chosen, for example oral administration.

In addition to antibody production, the immune response also included a cellular immune response, which for example can be demonstrated in lymphocyte proliferation assays. The effectiveness of a vaccine according to the invention is evident when comparing infected animals without or after prior immunization with the vaccine, showing on the one hand a reduction of the number of Dictyocaulus viviparus larvae shed with the faeces by a factor of at least 2, and on the other hand a reduction of the worm burden within the lungs of infected calves. Analysis of this comparison also demonstrated that vaccination significantly reduced the number of both non- inhibited and of inhibited Dictyocaulus viviparus larvae as counted from the lungs of sacrificed animals.

For the production of an immune response specific for parasitic nematodes, preferably of the genus Strongylida, preferably against Dictyocaulus spp, host animals are immunized with a vaccine according to the present invention using an immunization strategy, for example using a boosting strategy, according to standard procedures.

For analytical purposes, serum from immunized animals can be used to specifically detect parasitic nematodes, for example Dictyocaulus viviparus, independent from their condition of an inhibited or non- inhibited stage, e.g. using an antibody preparation linked to a detectable label.

Antibody can be purified according to known procedures. Suitable host animals for producing antibody are for example ruminants, like cattle and sheep, or mice, rats and rabbits. Apart from polyclonal antibody preparations, monoclonal antibody can be produced according to standard procedures, for example using the hybridoma technique on spleen cells obtained from immunized host animals. Monoclonal antibody can be identified for its specificity against either of PNMT, SOD, paramyosin, MSP, ACE or PDI. Production of monoclonal antibody can be performed according to known procedures. According to the invention, it is preferred that monoclonal antibody specific for PNMT is combined with at least one of antibody specific for SOD or antibody specific for paramyosin in order to detect both inhibited and non- inhibited Strongylida.

Polyclonal antibody, e.g. serum from immunized animals, or monoclonal antibody was used for analytical purposes to determine the presence of parasitic nematodes, namely Dictyocaulus viviparus in the host animal cattle. For this purpose, a sample of body fluid or a washing from an animal suspected of infection with Dictyocaulus viviparus, was homogenized and analysed in a specific immune reaction, generally using an ELISA format. Polyclonal antibody preparations or a combination of monoclonal antibody specific for PNMT with at least one antibody specific for SOD and an antibody specific for paramyosin was used for passive immunization of cattle, e.g. calves to provide at least a partial immunoprotection against subsequent infection with Dictyocaulus viviparus through ingestion. Improved results were found for antibody preparations that additionally contained antibody against MSP, optionally also antibodies against ACE and/or PDI.

It is a specific advantage of the present invention that a vaccine composition comprising both PNMT and at least one of SOD and paramyosin provides immunoprotection against inhibited and non- inhibited parasitic nematodes, especially their larvae, preferably against Dictyocaulus viviparus. Accordingly, an immune response can be elicited in vaccinated host animals that is also directed against the inhibited larvae of Dictyocaulus viviparus, resulting in a reduction or removal of inhibited larvae, which is suitable for interruption of the life cycle of said parasitic nematode. This is regarded a specific advantage because for example adult cattle may be infected by inhibited larvae of Dictyocaulus viviparus without showing symptoms i.e. they are not recognized as a source for contamination of pastures with infective eggs or larvae.

For an alternative use of antibody, in diagnostic applications, specific antibodies against each of PNMT, paramyosin, SOD, ACE, MSP, and PDI are provided by the present invention. Both the analytical antibodies and antibody used for treatment of animals can be polyclonal or monoclonal. For both polyclonal and monoclonal antibody to be used for the treatment of animals, e.g. for therapeutic purposes, it is preferred that their constant chains are in accordance with the animal species to be treated, e.g. an immunoreaction by the treated animal against the antibody according to the invention is avoided.

The present invention is now described in greater detail by way of examples with reference to the figures, wherein results of ELISAs from serum of immunized calves are shown: Figures 1 to 10 show ELISA results using PNMT as the antigen and serum from calves in vaccination trial I, wherein

• Figure 1 shows the titers of IgG of calves without immunization (control, animals 598, 596, 588, 950) and immunized with PNMT (animals 601, 756, 625, 915, 593, 580, 603, 748),

• Figure 2 shows the titers of IgG of calves immunized with a combination of PNMT, PDI and MSP (Mix, animals 749, 757, 914, 611, 544, 597, 586, 952) and controls without immunization,

• Figure 3 shows titers of IgGl of calves without immunization (control) and immunized with PNMT,

• Figure 4 shows the titers of IgGl of calves immunized with a combination of PNMT, PDI and MSP (Mix) and controls without immunization,

• Figure 5 shows titers of IgG2 of calves without immunization (control) and immunized with PNMT,

• Figure 6 shows the titers of IgG2 of calves immunized with a combination of PNMT, PDI and MSP (Mix) and controls without immunization,

• Figure 7 shows titers of IgA of calves without immunization (control) and immunized with PNMT,

• Figure 8 shows the titers of IgA of calves immunized with a combination of PNMT, PDI and MSP (Mix) and controls without immunization

• Figure 9 shows titers of IgM of calves without immunization (control) and immunized with PNMT, and

• Figure 10 shows the titers of IgM of calves immunized with a combination of PNMT, PDI and MSP (Mix) and controls without immunization.

Figures 11 to 19 show ELISA results using paramyosin of Dictyocaulus vivivparus as the antigen and serum from calves in vaccination trial II, wherein

• Figure 11 shows the titers of IgG of calves without immunization (control, animals 814, 795, 110, 805, 802, 808) and immunized with paramyosin (animals 812, 813, 806, 822), • Figure 12 shows the titers of IgG of calves without immunization (control) and immunized with Mix, comprising paramyosin, PNMT, MSP, PDI and ACE (animals 810, 790, 754, 816, 762, 807),

• Figure 13 shows the titers of IgGl of calves without immunization (control) and immunized with paramyosin,

• Figure 14 shows the titers of IgGl of calves without immunization (control) and immunized with Mix,

• Figure 15 shows the titers of IgG2 of calves without immunization (control) and immunized with paramyosin,

• Figure 16 shows the titers of IgG2 of calves without immunization (control) and immunized with Mix,

• Figure 17 shows the titers of IgA of calves without immunization (control) and immunized with paramyosin,

• Figure 18 shows the titers of IgA of calves without immunization (control) and immunized with Mix,

• Figure 19 shows the titers of IgM of calves without immunization (control) and immunized with paramyosin,

• Figure 20 shows the titers of IgM of calves without immunization (control) and immunized with Mix,

Figures 21 to 30 show ELISA results using PNMT of Dictyocaulus vivivparus as the antigen and serum from calves in vaccination trial II, wherein

• Figure 21 shows the titers of IgG of calves without immunization (control, animals 814, 795, 110, 805, 802, 808) and immunized with PNMT (animals 818, 809, 821, 761),

• Figure 22 shows the titers of IgG of calves without immunization (control) and immunized with Mix, comprising paramyosin, PNMT, MSP, PDI and ACE (animals 810, 790, 754, 816, 762, 807),

• Figure 23 shows the titers of IgGl of calves without immunization (control) and immunized with PNMT,

• Figure 24 shows the titers of IgGl of calves without immunization (control) and immunized with Mix,

• Figure 25 shows the titers of IgG2 of calves without immunization (control) and immunized with PNMT, • Figure 26 shows the titers of IgG2 of calves without immunization (control) and immunized with Mix,

• Figure 27 shows the titers of IgA of calves without immunization (control) and immunized with PNMT,

• Figure 28 shows the titers of IgA of calves without immunization (control) and immunized with Mix,

• Figure 29 shows the titers of IgM of calves without immunization (control) and immunized with PNMT, and

• Figure 30 shows the titers of IgM of calves without immunization (control) and immunized with Mix.

In the figures, numbers indicate individual calves and the legend to each figure gives the immunogenic protein and the adjuvant used, e.g. control animals (598, 596, 588 and 950) received adjuvant only without specific immunogenic protein.

Example 1: Analysis of differential gene expression in hvpobiosis induced (inhibited) and non- induced (non- inhibited) third-stage larvae of Dictyocaulus viviparus Generally, suppression subtractive hybridization, followed by differential screening of subtractive cDNA libraries was used to identify differentially expressed genes based on poly(A)⁺RNA of hypobiosis induced (L3i) and non- induced (L3ni) third-stage Dictyocaulus viviparus larvae.

To isolate poly(A)⁺ RNA, the exsheathed larvae were homogenized with a mortar and pestle in liquid nitrogen. PoIy(A)⁺ RNA was extracted using oligo(dT) cellulose beads from the Quick Prep™ Micro mRNA Purification Kit (Amersham Biosciences). The poly(A)⁺RNA yield was determined by measuring the absorbance at 260 nm. PoIy(A)⁺RNA of the two larval populations was transcribed into double stranded cDNA by using the SMART™ PCR cDNA Synthesis Kit (BD Clontech) according to the manufacturer's recommendations.

Suppression subtractive hybridization was performed with the PCR- Select™ cDNA Subtraction Kit (BD Clontech) according to the manufacturer's protocol. Briefly, following restriction-enzyme digestion of the cDNAs and adaptor ligation of the testers, two rounds of subtraction were done. In the forward subtraction, L3i-cDNA served as tester containing up- regulated transcripts. This tester was hybridized with driver cDNA of the L3ni to remove common gene sequences. In a reverse subtraction the L3ni cDNA served as tester and was hybridized with L3i cDNA as the driver. The subtracted, differentially expressed sequences of both larval populations were amplified using 27 primary and 12 secondary PCR cycles. To examine the efficiency of subtraction, subtracted and unsubtracted secondary PCR products of the L3i and L3ni were amplified using primers for an unspecified gene sequence known to be expressed in both larval populations. The sequences of the primers were 5'-ACG CGT TTA GCA CTA CTG GTT GT-3' (Seq.-ID No 1) and 5'-GGA CGG AAG CTG CTA CAA-3 ' (Seq.-ID No 2). PCR cycling was performed using the following temperature profile: denaturing at 94 °C for 30 s, annealing at 56 °C for 30 s, and extension at 68 °C for 2 min. To generate subtracted libraries, the secondary PCR products of the L3i and L3ni generated by suppression subtractive hybridization were directly cloned into the vector pCR™ 4- TOPO™ and transformed into E. coli strain One Shot™ TOPlO by the TOPO TA Cloning™ Kit for Sequencing (Invitrogen). Before generating subtracted libraries, randomly selected clones of the L3ni and L3i were checked for inserts using the nested primers of the secondary PCR.

The inserts of subtracted libraries were analyzed for differential expression by differential screening. Therefore, subtracted and unsubtracted primary PCR products of the L3i and L3ni were labeled with DIG-dUTP. Labeling of the cDNAs was done by secondary PCR with a DIG-dUTP:dTTP ratio of 1 :6 using the DIG DNA Labeling Mix (Roche), purified with CHROMA SPIN™- 100 Columns (BD Clontech), digested with Rsal, Smal, andEael (Roche) to remove adaptors and purified again with CHROMA SPIN™- 100 Columns.

The inserts of the subtracted libraries were amplified and arrayed in duplicate onto four positively charged nylon membranes (Roche) according to the protocol of the PCR-Select™ Differential Screening Kit (BD Clontech). The membranes were enclosed in a hybridization bag (Roche) and prehybridized with DIG Easy Hyb solution (Roche) containing 50 μl blocking solution (PCR-Select™ Differential Screening Kit, BD Clontech), and denatured at 99 °C for 10 min before quenching on ice. Prehybridization was performed at 42 °C for 90 min in a water bath with gentle shaking. Of each DIG-labeled probe 495 ng was denatured together with 50 μl blocking solution and added to 30 ml DIG Easy Hyb (16.5 ng probe/ml). This hybridization-solution was added to the membranes. Hybridization was done at 42 °C for 22 h in a water bath with gentle shaking followed by washing twice at RT (10 min/wash) in 2x SSC, 1% SDS and twice at 68 °C in 0.5x SSC, 0.1 % SDS (20 min/wash). The chemiluminescent detection was performed using the DIG High Prime Labeling and Detection Starter Kit II (Roche) according to the manufacturer's recommendations. Following exposure of the membranes to KODAK^® BioMax™ Light films (Amersham Biosciences) at RT for 40 min, the films were developed using KODAK^® GBX Developer and KODAK^® GBX Replenisher (Integra).

To confirm the results of the differential screening procedure, a further cDNA hybridization was performed. Briefly, the amplified inserts of the subtracted libraries were arrayed again in duplicate onto two positively charged nylon membranes (Roche). Freshly isolated poly(A)⁺ RNA (Quick Prep™ Micro mRNA Purification Kit, Amersham Biosciences) of the L3i and L3ni was used to generate DIG-labeled cDNA using the SMART™ PCR cDNA Synthesis Kit (BD Clontech) according to the manufacturer's instructions. The probes were then labeled with a DIG-dUTP:dTTP ratio of 1 :6 during LD PCR. To remove the SMART II oligonucleotides, the probes were purified with CHROMA SPIN™- 100 Columns (BD Clontech) according to the manufacturer's recommendations, digested with Rsal (Roche), and purified again with CHROMA SPIN™- 100 Columns. Preparation of the membranes, hybridization, and detection were carried out as described above with the following modifications: 25 ng probe/ml DIG Easy Hyb (Roche) were used and membranes were exposed for 90 min to the chemiluminescence films.

Example 2: Sequencing of differentially expressed genes

Plasmid DNA of the clones containing differentially expressed cDNAs were obtained using the Plasmid Midi Kit (Qiagen) and sequenced at the SEQLAB Sequence laboratories

(Gδttingen, Germany). The resulting sequence data were analyzed for identities to genes and proteins deposited in the NCBI database using the BLAST search program (available at http://www.ncbi.n1m.nih.gov/BLAST/).

As a result of suppression subtractive hybridization according to example 1, it was found that it is PNMT which is predominantly expressed in the inhibited stage of Dictyocaulus viviparus, whereas SOD and paramyosin are the proteins predominantly expressed in its non- inhibited stage. Example 3: Generating lull- length cDNA sequences

To obtain lull- length sequences of PNMT, SOD and paramyosin, rapid amplification of cDNA ends (RACE) was carried out using the SMART™ RACE cDNA Amplification Kit (BD Clontech). Briefly, poly( A)⁺RNA of the two larval populations was converted into first- strand cDNA and subsequently amplified using touchdown PCR. In 3 '-RACE the following gene specific primers were used:

5'-CACAAAATCGCCAAGAGCTAATGCGGTGGTATGA-S ' (Seq.-ID No 3) for PNMT, 5 '-GGCAAACGGTTGTCTAGCAGCTGGAGGTCATTATA-S ' (Seq.-ID No 4) for SOD, and 5 '-CTTGCCGATGCGAATCGAAAACTGCATGAGTT-S ' (Seq.-ID No 5) and 5 '-AAGCTAGTTTGGAAGATACCCAACGTCAGCTCCAACAAG-S ' (Seq.-ID NO 6), for paramyosin respectively.

The following gene specific primers were used in 5'-RACE:

5 '-ATTTCGCGTATCACTGTGCTGCCTCAACACCAC-S ' (Seq.-ID No 7) for PNMT, 5 '-ATACGTATCGCGCCCAATTCCAAGCGTTTAGTTTA-S ' (Seq.-ID No 8) for SOD, and 5 '-AGCGGTCGATTTCAAATTGCATATTCTTGCGAAGAG-S ' (Seq.-ID No 9), and 5 '-GAATAGCGATGGTGTTCTGAGCTTTCTCAAGGTCAACAATAAG-S ' (Seq.-ID No 10) for paramyosin, respectively.

Candidate bands were cut from the gel and ligated into pCR™ 4-TOPO™ vector (TOPO TA Cloning™ Kit for Sequencing, Invitrogen) followed by sequencing. Full-length cDNA sequences were obtained by overlapping fragments and subsequently compared to genes, proteins, and conserved domains deposited in the NCBI database using the BLAST search program to confirm that the full-length sequences are PNMT, SOD and paramyosin. For PNMT, five isotypes were identified, for SOD two isotypes. The sequences given are cDNA sequences, from which the respective amino acid sequences were translated. It is assumed that the number of isotypes is caused by post-transcriptional processing, e.g. by alternative splicing.

The sequence listings comprise for PNMT nucleic acid sequence amino acid sequence

Isotype 1 Seq.-ID No. 11 Seq.-ID No. 16

Isotype 2 Seq.-ID No. 12 Seq.-ID No. 17 for PNMT nucleic acid sequence amino acid sequence

Isotype 3 Seq.-ID No. 13 Seq.-ID No. 18

Isotype 4 Seq.-ID No. 14 Seq.-ID No. 19

Isotype 5 Seq.-ID No. 15 Seq.-ID No. 20;

for SOD nucleic acid sequence amino acid sequence

Isotype 1 Seq.-ID No. 21 Seq.-ID No. 23

Isotype 2 Seq.-ID No. 22 Seq.-ID No. 24;

for paramvosin nucleic acid sequence amino acid sequence

Seq.-ID No. 25 Seq.-ID No. 26;

for MSP nucleic acid sequence amino acid sequence Seq.-ID No. 27 Seq.-ID No. 28;

for ACE nucleic acid sequence amino acid sequence

Seq.-ID No. 29 Seq.-ID No. 30; and for PDI nucleic acid sequence amino acid sequence

Isotype 1 Seq.-ID No. 31 Seq.-ID No. 33

Isotype 2 Seq.-ID No. 32 Seq.-ID No. 34

Example 4: Production of PNMT. SOD and paramvosin bv heterologous expression

From each protein, the entire coding region with the exception of the start codon was ligated into pGEX-2T, pGEX-4T-3, pGEX-6P-3 (Amersham Biosciences), followed by PCR for incorporation of a BamHI restriction site at the 5 '-end and Notl (PNMT and paramyosin) and an EcoRI (SOD) restriction sites, respectively, at their 3 '-ends. Primers used for PNMT were (5^'-GGATCCGAGTCAGCAGACGGTG-S ', Seq.-ID No 35), PNMT rev (5'- GCGGCCGCAACAACAGAGTAGAATTAGGAAGTA-3', Seq.-ID No 36), for SOD (5'- GGATCCATACTCCACATTTCACTC -3', Seq.-ID No 37), SOD rev (5'-CTTAAGC CAATT CCAAGCGTTTAGTTTAGA-S', Seq.-ID No 38), for paramyosin (5'-GGAT CCTCTGCTAACTTGTACAG-3', Seq.-ID No 39), and paramyosin rev (5'-GCGGC CGCTTTTGCG GTCACCTTAGAAATC-3', Seq.-ID No 40). Resultant constructs were expressed in BL21 Star™ (DΕ3) One Shot^® chemically competent Escherichia coli (Invitrogen). The bacteria were grown to mid-log phase and isopropyl-beta-D-thiogalactoside (IPTG) was added to induce expression of PNMT, SOD and paramyosin, respectively. The cultures were incubated with vigorous agitation at 37 °C. The bacteria were harvested by centrifugation. After lysis of the cells, the expressed proteins containing a vector based GST- tag were purified using the MagneGST™ Protein Purification System (Promega) according to the manufacturer's recommendations and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

For isolation of PNMT, SOD and paramyosin, the amplification products containing their coding sequences were additionally ligated into vector pET41a (plus), which features a His- tag in addition to a GST-tag, using the same procedures as above. For purification, use of the GST-tag was made by employing the MagneGST protein purification system (Promega) in an automated procedure, using fast protein liquid chromatography (AKTA™FPLC, GE Healthcare) with GSTrap™ HP and HisTrap™ HP columns (GE Healthcare) according to the manufacturer's instructions. After elution, GST-tagged and His-tagged PNMT, SOD and paramyosin, respectively, were quantified in standard protein assays, SDS-PAGE or automated using a 2001 Bioanalyzer (Agilent Technologies).

Example 5: Active immunization of cattle for protective immunity against Dictyocaulus viviparus

Worm- free calves younger than six month at the start of the experiment were allocated into three groups of four each. Four calves were immunized three times intramuscularly in the neck at three week intervals with 200 μg recombinant protein according to Example 4 emulsified in 4 mg adjuvant (Alum) and Tris-buffer (10 mM, pH 7.4 or, preferably, 50 mM, pH 8.0) up to 1.5 ml. Another four calves were immunized three times intramuscularly in the neck at three week intervals with 200 μg recombinant protein according to Example 4, emulsified in 750 μg Quil A as adjuvant and Tris-buffer (10 mM, pH 7.4 or, preferably, 50 mM, pH 8.0) up to 1.5 ml. Control injections (four calves each) were prepared in the same way except with Elution buffer contained in the MagneGST™ Protein Purification System (Promega) replacing the antigen. All calves were challenged three weeks after the final injection by artificial infection with Dictyocaulus viviparus and necropsied five weeks later. Animals were observed for clinical normality every day with careful attention on clinical signs of lungworm infection. Faecal larvae counts were made at the days of injection, the day of challenge, and daily for the 28 days after challenge until necropsy. After necropsy, parasites were washed out of the lungs thoroughly to calculate final worm burden.

Furthermore, the parasites were determined to sex and developmental stage where possible and measured in length, analyzing 100 female and 100 male worms from each group of calves, with the worms collected evenly (25 each) from the calves.

Further protection trials done with each of PNMT, SOD and paramyosin only, combinations of PNMT and SOD only, PNMT and paramyosin only, SOD and paramyosin, and PNMT combined with both SOD and paramyosin showed immunization as well.

Vaccination trial I: Immunization with a) PNMT, b) PDI, and c) a combination of PNMT, PDI and MSP

Using the above isolated proteins in a protection trial, it was found that the best immunological protection could be obtained with a vaccine comprising PNMT, or even PNMT without further immunoreactive proteins, preferably using QuilA as the adjuvant. The analysis of the worm burden in immunologically challenged, i.e. artificially invected calves, could show that the greatest reduction of worm burden in the calves, analyzed after their necropsy, could be found for vaccine compositions comprising PNMT. The numbers of male and female parasites and their total number as well as their reduction in comparison to the control animals in table 1, which is shown with the enclosed figures.

Individual calves are identified by numbers, namely Control animals with Alum as 588, 596, 598, 950, animals with Mix/Alum as 611, 749, 757, 914, animals with Mix/Quil A as 544, 586, 597, 952, and animals with PNMT/QuilA 580, 593, 603, 748, the immunogenic proteins used for immunizations are indicated as control (no immunoreactive protein), Mix (PNMT, PDI, MSP in combination), and PNMT by itself, indicating adjuvants Alum and QuilA, respectively.

Reductions in worm burden were determined to an average of 32.56% for animals immunized with Mix in Alum, an average of 36.60% for animals immunized with Mix in Quil A, and an average of 48.99% for animals immunized with PNMT as the only immunogenic protein in Quil A, determined in comparison to control immunizations, i.e. without immunogenic protein. The results from table 1 are further supported by the observation that immunization with a vaccine comprising PNMT also leads to a reduction in length and width the of the individual parasitic worms.

Further, table 1 shows that male and female parasites are equally affected by the immune response elicited by the vaccine of the invention.

Further support for the effect of immunization with a vaccine comprising PNMT is found in the analysis of larval counts found in the faeces of these trial calves. Results are given in table 2 which is shown with the enclosed figures, giving total worm numbers for each calf, beginning at day 84, i.e. twenty-one days after immunochallenge until the date of necropsy, which is day 98.

Reductions in larval burden were determined to an average of 22.22% for animals (611, 749, 757, 914) immunized with Mix in Alum, an average of 64.74% for animals (544, 586, 597, 952) immunized with Mix in Quil A, and an average of 62.9% for animals (580, 593, 603, 748) immunized with PNMT as the only immunogenic protein in Quil A, determined in comparison to control immunizations, i.e. without immunogenic protein.

Further improvements in immunoprotection are obtained using known adjuvants and mixtures of these.

The results of sero-conversion from vaccination trial I are depicted in Figures 1 to 10 and demonstrate that a vaccine comprising PNMT, without further immunogenic protein, using either adjuvant Alum (animals 601, 756, 625 and 915) or QuilA (animals 593, 580, 603, and 748), induces antibody production in immunized calves specifically directed against Dictyocaulus viviparus. In detail, Figure 1 demonstrates induction of IgG by vaccines containing only PNMT as a specific immunogenic peptide, using Alum or Quil A as adjuvants, Figure 2 demonstrates the induction of a specific immune response of IgG directed against Dictyocaulus viviparus by vaccine compositions, comprising PNMT in admixture with further immunogenic protein, exemplified by the mixture (Mix) of PNMT, paramyosin, ACE, MSP, and PDI, using adjuvant Alum (animals 749, 757, 914 and 611), or adjuvant QuilA (animals 544, 597, 586, and 952), respectively. This immunoprotective effect of PNMT either without additional specific immunogenic protein, or in combination with additional immunogenic protein is further demonstrated for the same animals for IgGl in Figures 3 and 4, respectively, for IgG2 in Figures 5 and 6, respectively, for IgA in Figures 7 and 8, respectively, as well as for IgM in Figures 9 and 10, respectively.

Vaccination trial II: Immunization with a) combination of PNMT, paramvosin, ACE, MSP and PDI, b) paramvosin, and c) PNMT.

In a further immunization trial, a vaccine comprising a combination of proteins including PNMT were tested, namely a) PNMT, paramyosin, ACE, MSP and PDI were compared to b) paramyosin and c) PNMT without addition of further immunogenic protein. Interestingly analysis shows that the most significant reduction in worm burden was found for vaccine compositions comprising PNMT, preferably PNMT without addition of further immunogenic proteins. In this trial, QuilA was used consistently as the adjuvant. The reduction of worm burden after necropsy of trial calves is given in table 3, contained with the enclosed figures. Reduction of worm burden was 10.72% in animals (754, 762, 790, 807, 810, 816) vaccinated with a) the combination of PNMT, paramyosin, ACE, MSP and PDI, 68.81% in animals (761, 809, 818, 821) vaccinated with c) PNMT, and 54.44% in animals (806, 812, 813, 822) vaccinated with b) paramyosin, on average, in comparison to control immunizations, i.e. without immunogenic protein.

These results show that PNMT is the most effective immunogenic component of the vaccine composition, both for reducing the number of adult Dictyocaulus viviparus within infected animals, and for secretion of larvae with faeces.

Analysis of larvae secreted with faeces of artificially infected immunized trial calves is given in table 4, contained with the enclosed figures. Reductions in larval burden were determined to an average of 45.26% for animals (754, 762, 790, 807, 810, 816) immunized with a) the combination of PNMT, paramyosin, ACE, MSP and PDI, an average of 46.63% for animals (806, 812, 813, 822) immunized with b) paramyosin, and an average of 69.3% for animals (761, 809, 818, 821) immunized with PNMT as the only immunogenic protein, determined in comparison to control immunizations, i.e. without immunogenic protein. In tables 1 to 4, "Mean" designates average numbers of totals from the individual trial calves of one group, i.e. of calves treated identically.

The results of sero-conversion from vaccination trial II, i.e. the immunoprotective effect of paramyosin and Mix are depicted in Figures 11 to 20, demonstrating that a vaccine comprising paramyosin, without further immunogenic protein or in admixture with further immunogenic protein (Mix), induces antibody production in immunized calves specifically directed against Dictyocaulus viviparus paramyosin (used as the antigen in the ELISA). In detail, Figure 11 demonstrates induction of IgG by vaccines containing only paramyosin as a specific immunogenic peptide, Figure 12 demonstrates the induction of a specific immune response of IgG directed against Dictyocaulus viviparus by vaccine compositions, comprising paramyosin in admixture with further immunogenic protein, exemplified by the mixture a) (Mix) of PNMT, paramyosin, ACE, MSP and PDI.

This immunoprotective effect of paramyosin either without additional specific immunogenic protein, or in combination with additional immunogenic protein (Mix) is further demonstrated for the same animals for IgGl in Figures 13 and 14, respectively, for IgG2 in Figures 15 and 16, respectively, for IgA in Figures 17 and 18, respectively, as well as for IgM in Figures 19 and 20, respectively.

The immunoprotective effect of PNMT as the only immunogenic protein and Mix is further supported by the results depicted in Figures 21 to 30, showing that an immune response comprising a large variety of antibody classes, which are directed specifically against PNMT of Dictyocaulus viviparus is elicited by vaccine compositions comprising PNMT, optionally in combination with further protein.

Interestingly, further trials using a combination of PNMT and paramyosin or a combination of PNMT and SOD resulted in a less pronounced reduction of the worm burden of calves. Especially satisfactory results were determined for vaccine compositions comprising PNMT or paramyosin, even without further immunogenic peptide, and by vaccine compositions comprising a combination of PNMT with at least one of SOD and paramyosin. As an alternative to MSP or in addition to MSP, the addition of ACE and/or PDI to a vaccine comprising a combination of PNMT, paramyosin and SOD resulted in a further reduction of the worm burden.

Similar vaccination results for the reduction of worm and larval burden as well as seroconversion were obtained with vaccine preparations comprising nucleic acid sequences, e.g. DNA, encoding the immunogenic protein. Accordingly, the present invention also provides vaccines comprising nucleic acid sequences, preferably DNA, encoding the immunogenic protein, preferably PNMT and/or paramyosin, optionally in combination with MSP, ACE and/or PDI as well as immunogenic epitopes of these proteins. Preferably, nucleic acid sequences encoding the immunogenic protein or its epitopes, optionally encoding a combination of epitopes from PNMT and/or paramyosin, optionally in combination with MSP, ACE and/or PDI, were linked to promoter and/or enhancer sequences in 5 ' as well as linked to terminator and/or poly-adenylation elements in 3 '. Further, more than a first coding sequence can be contained between promoter and terminator elements, using IRES elements in 5 ' to the second coding sequence, arranged in 3 ' to the first coding sequence. Based on the immunogenic proteins of this invention, the skilled person is capable of constructing nucleic acid sequences suitable for the expression of the encoded immunogenic proteins upon administration to the ruminant to be immunized. For admininstration, i.m. injection of these nucleic acid constructs is sufficient for expression of the immunogenic proteins of the invention by the recipient's cells.

Example 6: Epitopes from PNMT, SOD and paramvosin to immunize cattle against Dictyocaulus viviparus

Epitopes, which are small regions of a protein molecule that the immune system recognizes and responds to, can be identified and localized in PNMT, SOD and paramyosin, respectively. This was done according to known methods using an epitope mapping technology, for example proteolytic digestion of proteins bound to immobilised antibodies, combined with matrix assisted laser desorption mass spectrometric identification of the remaining affinity- bound peptides. After identification and synthesis these peptides were used for immunization of cattle against Dictyocaulus viviparus in a protection treatment comparable to example 5, yielding comparable reductions in worm burden. The vaccination with epitopes instead of proteins can be advantageous to reduce the allergenic potential, which may be accompanied by atypical or unspecific immune responses.

Example 7: Production of antibodies to PNMT, SOD or paramvosin The present invention also relates to the use of PNMT, SOD and paramyosin as antigens to produce polyclonal antibodies or monoclonal antibodies that bind to or neutralize Dictyocaulus viviparus. Illustrative protocols for producing these antibodies are described for example by Harlow and Lane (Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (1988)) or Goding (Monoclonal antibodies. Principles and Practice, Academic Press, San Diego, California, USA (1996)).

Inoculum for polyclonal antibody production typically is prepared by dispersing the antigen in a physiologically tolerable diluent such as saline, to form an aqueous composition. An immunostimulatory amount of inoculum, with or without adjuvant, is administered to a mammal, and the inoculated mammal then is maintained for a time period sufficient for the antigen to induce protecting anύ-Dictyocaulus viviparus antigen antibodies. Boosting doses of the antigen may be used in individuals that are not already primed to respond to the antigen. The antibodies can be harvested and isolated to the extent desired by well known techniques, such as by alcohol fractionation and column chromatography, or by immunoaffinity chromatography; that is, by binding antigen to a chromatographic column packing like Sephadex™, passing the antiserum through the column, thereby retaining specific antibodies and separating out other immunoglobulins (IgGs) and contaminants, and then recovering purified antibodies by elution with a chaotropic agent, optionally followed by further purification.

Polyclonal antibodies were generated against PNMT, SOD or paramyosin only and combinations of these proteins (PNMT with SOD only, PNMT with paramyosin only, PNMT with both SOD and paramyosin, and SOD with paramyosin) by immunization with the entire protein or protein fragments or fusion peptides containing antigenic epitopes.

Generally a monoclonal antibody composition contains only one species of antibody binding to an epitope. Suitable antibodies in monoclonal form to PNMT, SOD or paramyosin can be prepared using conventional hybridoma technology. To form hybridomas from which a monoclonal antibody composition of the present invention is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from peripheral blood, lymph nodes or the spleen of a mammal hyperimmunized with the antigen. It is preferred that the myeloma cell line be from the same species as the lymphocytes. Spleenocytes are typically fused with myeloma cells using polyethylene glycol 1500. Fused hybrids are selected by their sensitivity to HAT. Hybridomas secreting the antibody molecules of this invention can be identified using an ELISA. Initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate specificity can produce a monoclonal antibody composition of the present invention. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules then can be isolated further by well-known techniques.

The monoclonal and polyclonal antibody compositions produced can be used in passive immunization to provide an immune reaction for the prevention or treatment of infection by Dictyocaulus viviparus. In this regard, the antibody preparation can be a polyclonal composition. Alternatively, an "engineered oligoclonal" mixture may be used, which is a mixture of monoclonal antibodies.

Example 8: Diagnostic assays of bovine samples for presence of Dictyocaulus viviparus antigens or specific antibodies against these

The nucleic acid molecules encoding PNMT, SOD and paramyosin, as well as proteins containing epitopes encoded by these nucleic acids and antibodies directed against these can be used as diagnostic reagents to detect infection by Strongylida, specially by Dictyocaulus viviparus.

An example for detecting presence or absence of mRNA or genomic DNA in a biological sample (e.g. faeces, serum or milk) is reverse transcription and amplification using polymerase chain reaction (PCR), respectively. These methods involve the use of synthetic oligonucleotides suitable as primers for PCR capable of hybridizing to nucleic acids. The sequences of such primers can easily be established by those skilled in the art to be specific to the nucleotide sequences given as Seq ID Nos 11 to 15 for PNMT, Seq ID Nos 21 and 22 for SOD and Seq ID No 25 for paramyosin, respectively. The primers generally can have from 10 to 40 nucleotides, preferably from 15 to 25 nucleotides. Furthermore, labelled nucleic acid probes capable of hybridizing to mRNA or genomic DNA specific for PNMT, SOD or paramyosin genes are suitable diagnostic tools. The nucleic acid probe can be, for example, a full-length nucleic acid or a portion thereof, such as an oligonucleotide sufficient to specifically hybridize to mRNA or genomic DNA of PNMT, SOD or paramyosin genes, respectively, for example in Northern or Southern hybridizations.

Further the antigens PNMT, SOD and paramyosin, synthetic peptides comprising epitopes specific for these antigens, or antibodies directed against these are useful in the production of diagnostic immunoassays for detecting the presence of Dictyocaulus viviparus antigens, preferably PNMT antigen and/or anti-Dictyocaulus viviparus antibodies, preferably anti- PNMT-antibodies, contained in a biological sample such as serum, preferably milk.

Either the Dictyocaulus viviparus antigen or antibody specific to the Dictyocaulus viviparus antigen, preferably PNMT or anti-PNMT-antibody is mixed with a sample suspected of containing Dictyocaulus viviparus antibody or antigen, respectively, and monitored for antigen-antibody binding. In a preferred embodiment, the antigen or antibody of the test is immobilized on a solid matrix such that the antigen or antibody is accessible to complementary antibody or antigen, respectively, from the sample to contact a surface of the matrix. The sample then is brought into contact with the surface of the matrix, and the surface is monitored for antigen-antibody binding. Preferably, the antigen or antibody will have a detectable label. Antibodies are polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used. The term "labelled" is intended to encompass direct labelling by coupling (i.e., physically linking) a detectable substance as well as indirect labelling by reactivity with another reagent that is directly labelled. Indirect labelling is for example the detection of a primary antibody using a fluorescently or otherwise labelled secondary antibody.

For example, the antigen or antibody can be used in an enzyme-linked immunosorbent assay (ELISA), in which antigen or antibody from a sample is bound to a solid phase and a specific enzyme-antibody or enzyme-antigen conjugate, preferably anti-PNMT Ab or PNMT, respectively, is used to detect and/or quantify antibody or antigen present in a sample.

Alternatively, a Western blot assay can be used, in which solubilized and separated antigens from a sample are bound to nitrocellulose membrane. The antibody then is detected by an enzyme or label-conjugated anti- immunoglobulin (Ig), such as horseradish peroxidase-Ig conjugate by incubating the membrane in the presence of a precipitable or detectable substrate. Western blot assays have the advantage of not requiring purity greater than 50% for the desired antigen.

The invention also encompasses kits for detecting the presence of Dictyocaulus viviparus in a biological sample. For example, the kit can comprise a labelled compound or agent to detect PNMT, possibly in combination with SOD or paramyosin in terms of nucleic acids, proteins or antibodies to them, e.g. a diagnostic kit can comprise nucleic acid probes specific for mRNA and/or DNA encoding paramyosin, PNMT and/or SOD, it can comprise monoclonal and/or polyclonal antibody specific for PNMT, and optionally in addition antibody specific for paramyosin and/or SOD or it can comprise protein containing epitopes PNMT (e.g. heterologously expressed full length natural sequences).

Claims

1. Vaccine suitable for eliciting immunoprotection against Dictyocaulus sp. in ruminants, characterized by comprising protein comprising immunoprotective epitopes of paramyosin and/or PNMT (phenyl ethanolamine-N-methyltransferase), each obtainable from Dictyocaulus sp.

2. Vaccine according to claim 1, characterized by the protein comprising immunoprotective epitopes of paramyosine is full length or partial length paramyosin and the protein comprising immunoprotective epitopes of PNMT is full length or partial length PNMT.

3. Vaccine according to one of the preceding claims, characterized by further comprising immunoprotective epitopes of at least one protein selected from the group comprising MSP (major sperm protein obtainable from Dictyocaulus spp.), ACE (acetylcholine esterase obtainable from Dictyocaulus spp.), PDI (protein disulfide isomerase obtainable from Dictyocaulus spp.), and SOD obtainable from Dictyocaulus spp.

4. Vaccine according to one of the preceding claims, characterized in that the epitopes are contained in proteins which are essentially identical to the natural translation product of the Dictyocaulus viviparus genome.

5. Vaccine according to one of the preceding claims, characterized in that Dictyocaulus sp. is Dictyocaulus viviparus.

6. Vaccine according to one of the preceding claims, characterized in that PNMT comprises at least a portion of one of Seq ID Nos 16 to 20, SOD comprises at least a portion of one of Seq ID Nos 23 or 24, paramyosin comprises at least a portion of Seq ID No 26, MSP comprises at least a portion of Seq ID No 28, ACE comprises at least a portion of Seq ID No 30, and PDI comprises at least a portion of one of Seq ID Nos 33 and 34.

7. Vaccine according to one of claims 1 to 5, characterized in that PNMT is encoded by a nucleic acid sequence hybridizing to one of Seq ID Nos 11 to 15, SOD is encoded by a nucleic acid sequence hybridizing to one of Seq ID Nos 21 and 22, paramyosin is encoded by a nucleic acid sequence hybridizing to Seq ID No 25, MSP is encoded by a nucleic acid sequence hybridizing to Seq ID No 27, ACE is encoded by a nucleic acid sequence hybridizing to Seq ID No 29, and PDI is encoded by a nucleic acid sequence hybridizing to one of Seq ID Nos 31 and 32.

8. Vaccine according to one of the preceding claims, wherein the ruminant is cattle.

9. Vaccine according to one of the preceding claims, characterized in that the protein comprising immunoprotective epitopes of paramyosin and/or PNMT (phenyl ethanolamine-N-methyltransferase), each obtainable from Dictyocaulus sp., is replaced by a nucleic acid sequence encoding the protein.

10. Paramyosin obtainable from Dictyocaulus sp.

11. PNMT (phenyl ethanolamine-N-methyltransferase) obtainable from Dictyocaulus sp.

12. Antibody, characterized by a specificity against a vaccine according to one of claims 1 to 8.

13. Analytical method for the determination of the presence of a parasitic nematode of the genus Strongylida in an animal, characterized by the use of an antibody according to claim 11.

14. Analytical method according to claim 13, characterized by the use of a protein comprising at least one epitope of paramyosin and/or at least one epitope of PNMT (phenyl ethanolamine-N-methyltransferase), each obtainable from Dictyocaulus viviparus.

15. Analytical method according to claim 13 or 14, characterized in that the method analyses milk or serum.

16. Method for passive immunization, characterized by the use of antibody according to claim 12.

17. Method for production of a vaccine for ruminants, characterized by producing a vaccine according to one of claims 1 to 8.

18. Method according to claim 17, characterized by heterologous expression of at least one of the peptide compounds.